Reloxin is currently used outside of the United States to treat neurological disorders, and has also been tested to for wrinkle reduction in 23 countries. The injectable has been undergoing testing specifically for glabellar and forehead lines since 2002, and the positive results so far have caught the attention of many researchers and plastic surgeons around the world.
While Botox continues to be the most sought-after nonsurgical procedure for men and women, a new option for getting rid of wrinkles on the forehead is on the horizon. Reloxin is a new type of botulinum toxin injection that has been undergoing testing in the United States for the past 13 months.
The March/April issue of the Archives of Facial Plastic Surgery recently published a report about the results of the studies, and reports that Reloxin is well tolerated and can maintain its anti-aging effects for over 13 months. These results are significantly better than the standard Botox treatment, which means many people could be asking for Reloxin over Botox if the new injection is approved for wrinkle reduction.
According to the Archives of Facial Plastic Surgery, the only reported side effects were injection site disorders, nervous system disorders (such as headaches), and eye disorders. Injection site and eye problems were reported about a week after the treatment and were then resolved, so there were no serious effects such as ‘droopy eyes’ or vision problems with Reloxin in these testing phases. (Source: Archives of Facial Plastic Surgery)
Reloxin will continue to undergo testing for the months ahead. The treatment has been developed by Medicis Pharmaceutical Corporation based in Scottsdale, Arizona and the company does intend to commercialize Reloxin in the United States as soon as it receives FDA approval. The Biologics License Application (BLA) for Reloxin to the FDA’s Division of Dermatology and Dental Products was submitted in March 2008.